Contemporary Pediatrics (@ContempPEDS) header
Contemporary Pediatrics (@ContempPEDS) profile picture

Practical Information for Today's Pediatrician

Joined January 2023
Photo by Contemporary Pediatrics (@ContempPEDS)Photo by Contemporary Pediatrics (@ContempPEDS)Photo by Contemporary Pediatrics (@ContempPEDS)Photo by Contemporary Pediatrics (@ContempPEDS)Photo by Contemporary Pediatrics (@ContempPEDS)Photo by Contemporary Pediatrics (@ContempPEDS)Photo by Contemporary Pediatrics (@ContempPEDS)Photo by Contemporary Pediatrics (@ContempPEDS)Photo by Contemporary Pediatrics (@ContempPEDS)Photo by Contemporary Pediatrics (@ContempPEDS)
FDA approves once-weekly somapacitan (Sogroya) for children aged ≥2.5 years with growth failure associated with Turner syndrome. The first long-acting GH approved for this indication could reduce the burden of daily injections. hubs.li/Q04FXTD90
9
Eczema was linked to 28% higher odds of sleep disturbance in a 26,395-patient pediatric primary care cohort presented at #ACAAI26. The takeaway for clinicians: ask about sleep, not just skin. hubs.li/Q04FScrT0 #Pediatrics #Eczema
17
FDA approves venglustat (Infilbray), the first treatment for neurological symptoms of type 3 Gaucher disease, for adults and children ≥15 kg. Phase 3 LEAP2MONO data showed improved ataxia and cognition scores vs ERT at 52 wks. hubs.li/Q04FS0550 #Pediatrics #RareDisease
26
FDA approves adrabetadex (Lembaz) for Niemann-Pick disease type C with neurologic onset before age 6. Approval was based on a 55% lower risk of death vs matched external controls. Boxed warning: permanent hearing loss. hubs.li/Q04Fzz_s0 #Pediatrics #RareDisease
2
2
107
Caregivers reported quick itch relief and lower eczema symptom scores in infants aged 3 to <24 mo using roflumilast cream 0.05% in the open-label INTEGUMENT-INFANT trial. FDA decision on the infant indication due Feb 23, 2027. hubs.li/Q04FwMGN0 #PedsDerm #AtopicDermatitis
22
Maternal autoantibody combinations may identify a non-genetic autism subtype linked to increased sibling recurrence risk, according to findings presented at #NSGC2026. Read more: hubs.li/Q04FqWy20
23
NEW: Tirzepatide reduced BMI by 18.5% over 72 weeks in adolescents with obesity, vs a 0.5% increase with placebo in the phase 3 SURMOUNT-ADOLESCENTS trial. Read the JAMA findings: hubs.li/Q04FqLM90
1
45
Language barriers may affect early peanut introduction. Research by James Senter and colleagues found infants from non-English-speaking families had 79% lower adjusted odds of peanut introduction at 6 months. Read more: hubs.li/Q04F9w2w0 @ACAAI #ACAAI26
36
Risankizumab demonstrated sustained efficacy through 52 weeks in children and adolescents with plaque psoriasis, with no new safety signals. Explore the pediatric trial findings: hubs.li/Q04F9pq80
32
Emily Becker, MD, FAAD, FAAP, discusses steroid-free topical therapy, skin barrier dysfunction, and treatment simplicity. Read the Q&A: hubs.li/Q04F2Fp10
29
Greater travel distance for pediatric surgery was linked to longer stays and higher charges. Senior author Cornelia L. Griggs, MD, MPH, FACS, highlighted the financial burden on families. hubs.li/Q04F2sx00
1
29
🥣 When should babies start solids? Are purees or baby-led weaning better? What about allergens? In her latest Notes on Nutrition column, Colleen Sloan, PA-C, RDN, shares practical guidance for pediatricians counseling families. 👇 Link in comments!
1
35
Can small changes in language improve vaccine conversations? At #AAP2026, Julie Sweetland, PhD, explained why pediatricians should focus less on hesitancy and more on helping parents understand vaccine benefits. Read more: hubs.li/Q04DVqHk0
25
Could air pollution contribute to pediatric eczema? A JAMA Pediatrics review linked certain pollutants to higher atopic dermatitis prevalence and health care visits, but not consistently to incidence or severity. hubs.li/Q04DNH2B0
19
FDA is investigating a serious risk of malignancy with Zolgensma (onasemnogene abeparvovec) for SMA after postmarketing reports confirmed vector integration near the GLI1 oncogene in 2 cases. More: hubs.li/Q04DNjqq0
26
Only 35.4% of in-season nirsevimab recipients received immunization within 7 days of birth, according to #IDWeek2026 data. @SanofiUS's Ayman Chit discusses gaps in RSV protection and opportunities for pediatricians to improve timely administration. hubs.li/Q04DrN8T0
32
Cenobamate is now under FDA review for PGTC seizures in patients 12 years and older, plus a separate filing to extend its focal-onset seizure indication to children. Read more: hubs.li/Q04Dlbq_0
25
Four rare disease treatments that matter for children and teens are up for FDA decisions this month, all between November 17 and 27. Here’s what pediatricians need to know about each one: hubs.li/Q04Dl8kk0
17
The CDC has reported the first pediatric flu death of the 2026–2027 season as influenza A(H1N1) activity rises earlier than usual. Pediatric ED visits and hospitalizations are also increasing. hubs.li/Q04DbDMV0
22